Yüklüyor......

Adverse Events Associated with Use of Digoxin Immune Fab Reported to the US Food and Drug Administration Adverse Event Reporting System, 1986–2019

BACKGROUND: Digoxin immune fab products, DigiBind and DigiFab, are antidotes for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose. Although approved by the US Food and Drug Administration (FDA) in 1986 (DigiBind) and 2001 (DigiFab), there r...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Drugs Real World Outcomes
Asıl Yazarlar: Wei, Shaokui, Niu, Manette T., Dores, Graça M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer International Publishing 2021
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8128941/
https://ncbi.nlm.nih.gov/pubmed/33721285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40801-021-00242-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!